rgnx-10q_20200930.htm
false Q3 0001590877 --12-31 P10Y true true P6Y P3Y true P5Y 2036-09-30 2023-09-30 2021-09-30 us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember P13Y9M18D P7Y6M P7Y4M24D P6Y3M19D P7Y4M24D 0001590877 2020-01-01 2020-09-30 xbrli:shares 0001590877 2020-10-30 iso4217:USD 0001590877 2020-09-30 0001590877 2019-12-31 iso4217:USD xbrli:shares 0001590877 2020-07-01 2020-09-30 0001590877 2019-07-01 2019-09-30 0001590877 2019-01-01 2019-09-30 0001590877 us-gaap:CommonStockMember 2020-06-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001590877 us-gaap:RetainedEarningsMember 2020-06-30 0001590877 2020-06-30 0001590877 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001590877 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001590877 us-gaap:CommonStockMember 2020-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001590877 us-gaap:RetainedEarningsMember 2020-09-30 0001590877 us-gaap:CommonStockMember 2019-06-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001590877 us-gaap:RetainedEarningsMember 2019-06-30 0001590877 2019-06-30 0001590877 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001590877 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001590877 us-gaap:CommonStockMember 2019-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001590877 us-gaap:RetainedEarningsMember 2019-09-30 0001590877 2019-09-30 0001590877 us-gaap:CommonStockMember 2019-12-31 0001590877 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001590877 us-gaap:RetainedEarningsMember 2019-12-31 0001590877 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001590877 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001590877 us-gaap:CommonStockMember 2018-12-31 0001590877 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001590877 us-gaap:RetainedEarningsMember 2018-12-31 0001590877 2018-12-31 0001590877 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001590877 us-gaap:AccountingStandardsUpdate201602Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001590877 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001590877 us-gaap:AccountingStandardsUpdate201802Member us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001590877 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001590877 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001590877 rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember 2020-01-01 2020-09-30 0001590877 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2020-09-30 0001590877 us-gaap:CertificatesOfDepositMember 2020-09-30 0001590877 us-gaap:CorporateBondSecuritiesMember 2020-09-30 0001590877 us-gaap:EquitySecuritiesMember 2020-09-30 0001590877 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2019-12-31 0001590877 us-gaap:CertificatesOfDepositMember 2019-12-31 0001590877 us-gaap:CorporateBondSecuritiesMember 2019-12-31 0001590877 us-gaap:EquitySecuritiesMember 2019-12-31 0001590877 srt:MaximumMember 2020-07-01 2020-09-30 0001590877 srt:MaximumMember 2020-01-01 2020-09-30 0001590877 srt:MaximumMember 2019-07-01 2019-09-30 0001590877 srt:MaximumMember 2019-01-01 2019-09-30 0001590877 us-gaap:InvestmentIncomeMember srt:MaximumMember 2020-07-01 2020-09-30 0001590877 us-gaap:InvestmentIncomeMember srt:MaximumMember 2020-01-01 2020-09-30 0001590877 us-gaap:InvestmentIncomeMember srt:MaximumMember 2019-07-01 2019-09-30 0001590877 us-gaap:InvestmentIncomeMember srt:MaximumMember 2019-01-01 2019-09-30 0001590877 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2019-09-30 0001590877 us-gaap:CorporateBondSecuritiesMember 2019-09-30 rgnx:Security 0001590877 us-gaap:EquitySecuritiesMember 2020-07-01 2020-09-30 0001590877 us-gaap:EquitySecuritiesMember 2020-01-01 2020-09-30 0001590877 us-gaap:EquitySecuritiesMember 2019-07-01 2019-09-30 0001590877 us-gaap:EquitySecuritiesMember 2019-01-01 2019-09-30 0001590877 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember 2020-09-30 0001590877 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2020-09-30 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember 2020-09-30 0001590877 us-gaap:CashEquivalentsMember 2020-09-30 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001590877 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2020-09-30 0001590877 us-gaap:CertificatesOfDepositMember 2020-09-30 0001590877 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0001590877 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2020-09-30 0001590877 us-gaap:EquitySecuritiesMember 2020-09-30 0001590877 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001590877 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001590877 us-gaap:FairValueInputsLevel1Member rgnx:CashEquivalentsAndMarketableSecuritiesMember 2020-09-30 0001590877 us-gaap:FairValueInputsLevel2Member rgnx:CashEquivalentsAndMarketableSecuritiesMember 2020-09-30 0001590877 rgnx:CashEquivalentsAndMarketableSecuritiesMember 2020-09-30 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2019-12-31 0001590877 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2019-12-31 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember 2019-12-31 0001590877 us-gaap:CashEquivalentsMember 2019-12-31 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001590877 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2019-12-31 0001590877 us-gaap:CertificatesOfDepositMember 2019-12-31 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2019-12-31 0001590877 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2019-12-31 0001590877 us-gaap:EquitySecuritiesMember 2019-12-31 0001590877 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001590877 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001590877 us-gaap:FairValueInputsLevel1Member rgnx:CashEquivalentsAndMarketableSecuritiesMember 2019-12-31 0001590877 us-gaap:FairValueInputsLevel2Member rgnx:CashEquivalentsAndMarketableSecuritiesMember 2019-12-31 0001590877 rgnx:CashEquivalentsAndMarketableSecuritiesMember 2019-12-31 0001590877 rgnx:LaboratoryAndManufacturingEquipmentMember 2020-09-30 0001590877 rgnx:LaboratoryAndManufacturingEquipmentMember 2019-12-31 0001590877 us-gaap:ComputerEquipmentMember 2020-09-30 0001590877 us-gaap:ComputerEquipmentMember 2019-12-31 0001590877 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001590877 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001590877 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001590877 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001590877 rgnx:NineThousandEightHundredFourMedicalCenterDriveMember country:MD 2018-08-01 2018-08-31 0001590877 rgnx:NineThousandEightHundredFourMedicalCenterDriveMember country:MD 2020-01-01 2020-09-30 0001590877 rgnx:NineThousandEightHundredFourMedicalCenterDriveMember country:MD 2018-08-31 utr:sqft 0001590877 rgnx:NineThousandEightHundredFourMedicalCenterDriveMember 2020-01-01 2020-09-30 0001590877 rgnx:NineThousandEightHundredFourMedicalCenterDriveMember 2020-09-30 0001590877 rgnx:NineThousandSevenHundredTwelveMedicalCenterDriveMember stpr:MD 2020-01-01 2020-09-30 0001590877 rgnx:NineThousandSevenHundredTwelveMedicalCenterDriveMember stpr:MD 2018-04-30 0001590877 rgnx:NineThousandSevenHundredTwelveMedicalCenterDriveMember stpr:MD 2018-04-01 2018-04-30 0001590877 rgnx:NineThousandSevenHundredTwelveMedicalCenterDriveMember us-gaap:SubsequentEventMember country:MD 2020-10-01 2020-10-31 0001590877 rgnx:NineThousandSevenHundredTwelveMedicalCenterDriveMember us-gaap:SubsequentEventMember country:MD 2020-10-31 0001590877 rgnx:NineThousandSixHundredBlackwellRoadMember country:MD 2016-01-01 2016-01-31 0001590877 rgnx:NineThousandSixHundredBlackwellRoadMember country:MD 2020-01-01 2020-09-30 0001590877 rgnx:NineThousandSixHundredBlackwellRoadMember country:MD 2016-01-31 0001590877 rgnx:NineThousandSixHundredBlackwellRoadMember srt:ScenarioForecastMember country:MD 2020-11-30 0001590877 rgnx:NineThousandSixHundredBlackwellRoadMember srt:ScenarioForecastMember country:MD 2020-11-01 2020-11-30 0001590877 rgnx:FourHundredMadisonLeaseMember stpr:NY 2016-05-01 2016-05-31 0001590877 rgnx:FourHundredMadisonLeaseMember stpr:NY 2016-05-31 0001590877 rgnx:MarylandAndNewYorkMember 2020-01-01 2020-09-30 0001590877 rgnx:NineThousandSixHundredBlackwellRoadMember 2020-01-01 2020-09-30 0001590877 rgnx:NineThousandSixHundredBlackwellRoadMember 2020-07-01 2020-09-30 xbrli:pure rgnx:ProductCandidate 0001590877 rgnx:NAVTechnologyPlatformMember srt:MinimumMember 2020-09-30 0001590877 rgnx:NAVTechnologyPlatformMember 2020-09-30 0001590877 us-gaap:AccountsReceivableMember 2019-12-31 0001590877 rgnx:ContractAssetsMember 2019-12-31 0001590877 us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0001590877 rgnx:ContractAssetsMember 2020-01-01 2020-09-30 0001590877 us-gaap:AccountsReceivableMember 2020-09-30 0001590877 rgnx:ContractAssetsMember 2020-09-30 0001590877 rgnx:AveXisIncorporationMember 2020-01-01 2020-09-30 0001590877 rgnx:AveXisIncorporationMember 2020-09-30 0001590877 rgnx:ZolgensmaMember 2020-09-30 0001590877 us-gaap:SubsequentEventMember rgnx:AveXisIncorporationMember 2020-10-01 2020-10-31 0001590877 us-gaap:LicenseMember 2020-01-01 2020-09-30 0001590877 us-gaap:LicenseMember 2019-01-01 2019-09-30 0001590877 rgnx:ZolgensmaRoyaltiesMember 2020-07-01 2020-09-30 0001590877 rgnx:ZolgensmaRoyaltiesMember 2019-07-01 2019-09-30 0001590877 rgnx:ZolgensmaRoyaltiesMember 2020-01-01 2020-09-30 0001590877 rgnx:ZolgensmaRoyaltiesMember 2019-01-01 2019-09-30 0001590877 rgnx:AchievementOfSalesBasedMilestoneForZolgensmaMember 2020-07-01 2020-09-30 0001590877 rgnx:AchievementOfSalesBasedMilestoneForZolgensmaMember 2020-01-01 2020-09-30 0001590877 rgnx:AveXisIncorporationMember 2020-07-01 2020-09-30 0001590877 rgnx:AveXisIncorporationMember 2019-07-01 2019-09-30 0001590877 rgnx:AveXisIncorporationMember 2019-01-01 2019-09-30 0001590877 rgnx:AveXisIncorporationMember rgnx:MarchTwoZeroOneFourLicenseAgreementMember 2020-09-30 0001590877 rgnx:AveXisIncorporationMember rgnx:MarchTwoZeroOneFourLicenseAgreementMember 2019-12-31 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember 2020-04-01 2020-04-01 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2020-10-01 2020-10-31 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2018-11-29 2018-11-30 0001590877 rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2020-04-01 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2018-11-01 2018-11-30 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2020-07-01 2020-09-30 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2020-01-01 2020-09-30 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2020-09-30 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2020-05-31 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2020-05-30 2020-05-31 0001590877 rgnx:TwoThousandAndFifteenEquityIncentivePlanMember 2020-01-01 2020-01-31 0001590877 rgnx:TwoThousandAndFifteenEquityIncentivePlanMember 2020-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001590877 us-gaap:EmployeeStockMember 2020-07-01 2020-09-30 0001590877 us-gaap:EmployeeStockMember 2019-07-01 2019-09-30 0001590877 us-gaap:EmployeeStockMember 2020-01-01 2020-09-30 0001590877 us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0001590877 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001590877 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001590877 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001590877 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001590877 rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember 2019-12-31 0001590877 rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember 2020-09-30 0001590877 rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember 2019-01-01 2019-12-31 0001590877 rgnx:TwoThousandAndFifteenEquityIncentivePlanMember 2020-01-01 2020-09-30 0001590877 rgnx:TwoThousandFifteenEmployeeStockPurchasePlanMember 2020-01-01 2020-01-31 0001590877 rgnx:TwoThousandFifteenEmployeeStockPurchasePlanMember 2020-09-30 0001590877 rgnx:TwoThousandFifteenEmployeeStockPurchasePlanMember 2020-01-01 2020-09-30 0001590877 us-gaap:ServiceAgreementsMember us-gaap:ResearchAndDevelopmentExpenseMember rgnx:FOXKISERLimitedLiabilityPartnershipMember 2020-07-01 2020-09-30 0001590877 us-gaap:ServiceAgreementsMember us-gaap:ResearchAndDevelopmentExpenseMember rgnx:FOXKISERLimitedLiabilityPartnershipMember 2020-01-01 2020-09-30 0001590877 us-gaap:ServiceAgreementsMember us-gaap:ResearchAndDevelopmentExpenseMember rgnx:FOXKISERLimitedLiabilityPartnershipMember 2019-07-01 2019-09-30 0001590877 us-gaap:ServiceAgreementsMember us-gaap:ResearchAndDevelopmentExpenseMember rgnx:FOXKISERLimitedLiabilityPartnershipMember 2019-01-01 2019-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001590877 rgnx:EmployeeStockPurchasePlanMember 2020-07-01 2020-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001590877 rgnx:EmployeeStockPurchasePlanMember 2019-07-01 2019-09-30 0001590877 rgnx:EmployeeStockPurchasePlanMember 2020-01-01 2020-09-30 0001590877 rgnx:EmployeeStockPurchasePlanMember 2019-01-01 2019-09-30

Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission File Number 001-37553

 

REGENXBIO Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

47-1851754

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

9600 Blackwell Road, Suite 210

Rockville, MD

 

20850

(Address of principal executive offices)

 

(Zip Code)

(240) 552-8181

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

RGNX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of October 30, 2020, there were 37,408,448 shares of the registrant’s common stock, par value $0.0001 per share, issued and outstanding.

 

 

 


Table of Contents

 

REGENXBIO INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020

TABLE OF CONTENTS

 

 

 

PART I—FINANCIAL INFORMATION

 

 

 

 

 

 

 

Item 1.

 

Financial Statements (Unaudited)

 

3

 

 

Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019

 

3

 

 

Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2020 and 2019

 

4

 

 

Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2020 and 2019

 

5

 

 

Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019

 

7

 

 

Notes to Consolidated Financial Statements

 

8

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

23

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

34

Item 4.

 

Controls and Procedures

 

34

 

 

 

 

 

 

 

PART II—OTHER INFORMATION

 

 

 

 

 

 

 

Item 1.

 

Legal Proceedings

 

35

Item 1A.

 

Risk Factors

 

35

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

38

Item 3.

 

Defaults Upon Senior Securities

 

38

Item 4.

 

Mine Safety Disclosures

 

38

Item 5.

 

Other Information

 

38

Item 6.

 

Exhibits

 

39

Signatures

 

40

 

 

 


Table of Contents

 

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “assume,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would” or by variations of such words or by similar expressions. We have based these forward-looking statements on our current expectations and assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate under the circumstances. However, whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, uncertainties, assumptions and other important factors, including, but not limited to:

 

the impact of the COVID-19 pandemic on our business, operations and preclinical and clinical development timelines and plans;

 

the ability to obtain and maintain regulatory approval of our product candidates and the labeling for any approved products;

 

the timing of enrollment, commencement and completion and the success of our clinical trials;

 

the timing of commencement and completion and the success of preclinical studies conducted by us and our development partners;

 

the timely development and launch of new products;

 

the scope, progress, expansion and costs of developing and commercializing our product candidates;

 

our ability to obtain and maintain intellectual property protection for our product candidates and technology;

 

our expectations regarding the development and commercialization of product candidates currently being developed by third parties that utilize our technology;

 

our anticipated growth strategies;

 

our expectations regarding competition;

 

the anticipated trends and challenges in our business and the market in which we operate;

 

our ability to attract or retain key personnel;

 

the size and growth of the potential markets for our product candidates and the ability to serve those markets;

 

the rate and degree of market acceptance of any of our products that are approved;

 

our ability to establish and maintain development partnerships;

 

our expectations regarding our expenses and revenue;

 

our expectations regarding the outcome of legal proceedings, including our arbitration with Abeona Therapeutics Inc. regarding license fees that have not been paid to us and our ability to recover such unpaid fees;

 

our expectations regarding regulatory developments in the United States and foreign countries; and

 

the use or sufficiency of our cash and cash equivalents and needs for additional financing.

You should carefully read the factors discussed in the sections titled “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2019 and in our other filings with the U.S. Securities and Exchange Commission (the SEC) for additional discussion of the risks, uncertainties, assumptions and other important factors that could cause our actual results or developments to differ materially and adversely from those projected in the forward-looking statements. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on us or our businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially and adversely from those projected in the forward-looking statements. These forward-looking statements speak only as of the date of this report. Except as required by law, we disclaim any duty to update any forward-looking statements, whether as a result of new information, future events or otherwise.

1


Table of Contents

 

Available Information

We file annual, quarterly, and current reports, proxy statements, and other documents with the SEC under the Exchange Act. You may obtain any reports, proxy and information statements, and other information that we file electronically with the SEC at www.sec.gov.

You also may view and download copies of our SEC filings free of charge at our website, www.regenxbio.com, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information contained on, or that can be accessed through, our website will not be deemed to be incorporated by reference in, and is not considered part of, this Quarterly Report on Form 10-Q. Investors should also note that we use our website, as well as SEC filings, press releases, public conference calls and webcasts, to announce financial information and other material developments regarding our business. We use these channels, as well as any social media channels listed on our website, to communicate with investors and members of the public about our business. It is possible that the information that we post on our social media channels could be deemed material information. Therefore, we encourage investors, the media and others interested in our company to review the information that we post on our social media channels.

As used in this Quarterly Report on Form 10-Q, the terms “REGENXBIO,” “we,” “us,” “our” or the “Company” mean REGENXBIO Inc. and its subsidiaries, on a consolidated basis, unless the context indicates otherwise.

NAV, REGENXBIO and the REGENXBIO logos are our registered trademarks. Any other trademarks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders.

2


Table of Contents

 

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

REGENXBIO INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except per share data)

 

 

 

September 30, 2020

 

 

December 31, 2019

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

93,220

 

 

$

69,514

 

Marketable securities

 

 

148,305

 

 

 

226,696

 

Accounts receivable, net

 

 

122,116

 

 

 

38,148

 

Prepaid expenses

 

 

16,112

 

 

 

6,475

 

Other current assets

 

 

7,197

 

 

 

4,199

 

Total current assets

 

 

386,950

 

 

 

345,032

 

Marketable securities

 

 

48,272

 

 

 

103,785

 

Accounts receivable, net

 

 

3,564

 

 

 

4,155

 

Property and equipment, net

 

 

38,871

 

 

 

28,973

 

Operating lease right-of-use assets

 

 

57,827

 

 

 

10,078

 

Restricted cash

 

 

1,330

 

 

 

1,330

 

Other assets

 

 

4,360

 

 

 

4,555

 

Total assets

 

$

541,174

 

 

$

497,908

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

15,244

 

 

$

6,409

 

Accrued expenses and other current liabilities

 

 

44,356

 

 

 

24,846

 

Deferred revenue

 

 

449

 

 

 

 

Operating lease liabilities

 

 

3,564

 

 

 

2,421

 

Total current liabilities

 

 

63,613

 

 

 

33,676

 

Deferred revenue

 

 

3,895

 

 

 

3,333

 

Operating lease liabilities

 

 

57,461

 

 

 

8,874

 

Other liabilities

 

 

545

 

 

 

1,828

 

Total liabilities

 

 

125,514

 

 

 

47,711

 

Stockholders’ equity

 

 

 

 

 

 

 

 

Preferred stock; $0.0001 par value; 10,000 shares authorized, and no shares issued

   and outstanding at September 30, 2020 and December 31, 2019

 

 

 

 

 

 

Common stock; $0.0001 par value; 100,000 shares authorized at September 30, 2020

   and December 31, 2019; 37,404 and 36,992 shares issued and outstanding at

   September 30, 2020 and December 31, 2019, respectively

 

 

4

 

 

 

4

 

Additional paid-in capital

 

 

658,224

 

 

 

627,810

 

Accumulated other comprehensive income

 

 

263

 

 

 

205

 

Accumulated deficit

 

 

(242,831

)

 

 

(177,822

)

Total stockholders’ equity

 

 

415,660

 

 

 

450,197

 

Total liabilities and stockholders’ equity

 

$

541,174

 

 

$

497,908

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 

3


Table of Contents

 

REGENXBIO INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(unaudited)

(in thousands, except per share data)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

License and royalty revenue

 

$

98,912

 

 

$

14,700

 

 

$

133,122

 

 

$

23,465

 

Total revenues

 

 

98,912

 

 

 

14,700

 

 

 

133,122

 

 

 

23,465

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

17,364

 

 

 

2,494

 

 

 

25,457

 

 

 

4,450

 

Research and development

 

 

43,968

 

 

 

35,692

 

 

 

119,114

 

 

 

90,378

 

General and administrative

 

 

15,859

 

 

 

12,402

 

 

 

46,246

 

 

 

37,365

 

Provision for credit losses and other

 

 

7,770

 

 

 

8

 

 

 

7,887

 

 

 

(54

)

Total operating expenses

 

 

84,961

 

 

 

50,596

 

 

 

198,704

 

 

 

132,139

 

Income (loss) from operations

 

 

13,951

 

 

 

(35,896

)

 

 

(65,582

)

 

 

(108,674

)

Other Income (Loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income from licensing

 

 

1,444

 

 

 

716

 

 

 

4,141

 

 

 

2,091

 

Investment income (loss)

 

 

(6,607

)

 

 

431

 

 

 

(4,071

)

 

 

37,950

 

Total other income (loss)

 

 

(5,163

)

 

 

1,147

 

 

 

70

 

 

 

40,041

 

Income (loss) before income taxes

 

 

8,788

 

 

 

(34,749

)

 

 

(65,512

)

 

 

(68,633

)

Income Tax Benefit

 

 

3

 

 

 

165

 

 

 

503

 

 

 

364

 

Net income (loss)

 

$

8,791

 

 

$

(34,584

)

 

$

(65,009

)

 

$

(68,269

)

Other Comprehensive Income (Loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities, net

 

 

(487

)

 

 

(108

)

 

 

58

 

 

 

1,043

 

Total other comprehensive income (loss)

 

 

(487

)

 

 

(108

)

 

 

58

 

 

 

1,043

 

Comprehensive income (loss)

 

$

8,304

 

 

$

(34,692

)

 

$

(64,951

)

 

$

(67,226

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.24

 

 

$

(0.94

)

 

$

(1.75

)

 

$

(1.86

)

Diluted

 

$

0.23

 

 

$

(0.94

)

 

$

(1.75

)

 

$

(1.86

)

Weighted-average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

37,342

 

 

 

36,813

 

 

 

37,234

 

 

 

36,618

 

Diluted

 

 

38,877

 

 

 

36,813

 

 

 

37,234

 

 

 

36,618

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 

4


Table of Contents

 

REGENXBIO INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands)

 

 

 

Three Months Ended September 30, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

Balances at June 30, 2020

 

 

37,291

 

 

$

4

 

 

$

648,729

 

 

$

750

 

 

$

(251,622

)

 

$

397,861

 

Exercise of stock options

 

 

74

 

 

 

 

 

 

268

 

 

 

 

 

 

 

 

 

268

 

Issuance of common stock under employee

   stock purchase plan

 

 

38

 

 

 

 

 

 

1,192

 

 

 

 

 

 

 

 

 

1,192

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

8,035

 

 

 

 

 

 

 

 

 

8,035

 

Unrealized loss on available-for-sale securities, net

 

 

 

 

 

 

 

 

 

 

 

(487

)

 

 

 

 

 

(487

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8,791

 

 

 

8,791

 

Balances at September 30, 2020

 

 

37,404

 

 

$

4

 

 

$

658,224

 

 

$

263

 

 

$

(242,831

)

 

$

415,660

 

 

 

 

 

Three Months Ended September 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

Balances at June 30, 2019

 

 

36,752

 

 

$

4

 

 

$

610,891

 

 

$

471

 

 

$

(116,774

)

 

$

494,592

 

Exercise of stock options

 

 

62

 

 

 

 

 

 

384

 

 

 

 

 

 

 

 

 

384

 

Issuance of common stock under employee

   stock purchase plan

 

 

26

 

 

 

 

 

 

949

 

 

 

 

 

 

 

 

 

949

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

7,162

 

 

 

 

 

 

 

 

 

7,162

 

Unrealized loss on available-for-sale securities, net

 

 

 

 

 

 

 

 

 

 

 

(108

)

 

 

 

 

 

(108

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(34,584

)

 

 

(34,584

)

Balances at September 30, 2019

 

 

36,840

 

 

$

4

 

 

$

619,386

 

 

$

363

 

 

$

(151,358

)

 

$

468,395

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

5


Table of Contents

 

REGENXBIO INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands)

 

 

 

Nine Months Ended September 30, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2019

 

 

36,992

 

 

$

4

 

 

$

627,810

 

 

$

205

 

 

$

(177,822

)

 

$

450,197

 

Exercise of stock options

 

 

356

 

 

 

 

 

 

4,247

 

 

 

 

 

 

 

 

 

4,247

 

Issuance of common stock under employee

   stock purchase plan

 

 

55

 

 

 

 

 

 

1,799

 

 

 

 

 

 

 

 

 

1,799

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

24,368

 

 

 

 

 

 

 

 

 

24,368

 

Unrealized gain on available-for-sale securities, net

 

 

 

 

 

 

 

 

 

 

 

58

 

 

 

 

 

 

58

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(65,009

)

 

 

(65,009

)

Balances at September 30, 2020

 

 

37,404

 

 

$

4

 

 

$

658,224

 

 

$

263

 

 

$

(242,831

)

 

$

415,660

 

 

 

 

 

Nine Months Ended September 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2018

 

 

36,120

 

 

$

4

 

 

$

592,580

 

 

$

(720

)

 

$

(83,016

)

 

$

508,848

 

Adoption of ASU 2016-02 (Topic 842)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(33

)

 

 

(33

)

Adoption of ASU 2018-02

 

 

 

 

 

 

 

 

 

 

 

40

 

 

 

(40

)

 

 

 

Exercise of stock options

 

 

684

 

 

 

 

 

 

5,513

 

 

 

 

 

 

 

 

 

5,513

 

Issuance of common stock under employee

   stock purchase plan

 

 

36

 

 

 

 

 

 

1,314

 

 

 

 

 

 

 

 

 

1,314

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

19,979